ANI reaffirms 2026 total net revenue guidance of $1.08 bln to $1.14 bln
Company lowers 2026 Cortrophin Gel net revenue outlook to $520 mln-$540 mln from $540 mln-$575 mln
ANI maintains 2026 adjusted non-GAAP EBITDA guidance of $285 mln-$300 mln and EPS of $9.19-$9.69
Overview
US biopharmaceutical firm's Q2 net revenue grew 25.9% yr/yr to $266.0 mln
Adjusted EPS for Q2 beat analyst expectations
Company authorized a $100 mln share repurchase program through May 2029
Result Drivers
Cortrophin Gel volume - Co said Q2 growth for Cortrophin Gel was driven primarily by increased volume in specialty areas including Nephrology, Neurology, Ophthalmology, Pulmonology and Rheumatology
Gout expansion - Co said sales force expansion targeting podiatrists and primary care physicians for Cortrophin Gel in acute gouty arthritis flares was fully operational by end of June, with positive demand metrics
Generics launches - Co said generics net revenue growth was driven by new product launches and continued strength in partnered generic launch that began in Q3 2025
Key details and analyst coverage
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Adjusted EPS
Beat
$2.21
$2.05 (8 Analysts)
Q2 EPS
$1.05
Q2 Net Income
$24.70 mln
Q2 Adjusted EBITDA
$71.60 mln
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for ANI Pharmaceuticals, Inc. is $105.00, about 27.1% above its August 6 closing price of $82.63
The stock recently traded at 8 times the next 12-month earnings vs. a P/E of 8 three months ago
ANIP•
